IL18 and melanoma: Taken together, the negative correlation between Erdr1 and IL-18 suggests a potential anti-inflammatory effect that occurs through regulation of inflammatory response-related molecules such as HSP90 and STAT3, which are also candidates to be targeted for melanoma therapy (Figure 1).